Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Content from other channels on our network

Research hub to advance energy transition

ARRC seeks feedback on alternative waste treatment method

The next phase of Australia's energy transition demands specialised engagement and a focus on delivery

Coal and LNG export demand could dry up before 2040: report

Electrification the focus for COP31

AirTrunk and European Energy to build renewables in the Hunter

Australian Vanadium secures funding for electrolyte manufacturing

SPEE3D launches Darwin manufacturing facility

Delorean finalises funding for Sydney renewable gas project

Accuris adds Australian legislation to Engineering Workbench

Closing the sensory gap with no- and low-alcohol wine

Balancing Food Safety, Traceability and Growth in a Changing Manufacturing Environment

Electrical technique for dehydrating milk, without heat

Ballarat food manufacturer plans to expand with new facility

$70m facility to strengthen local packaging production